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PUBERTY plays a dual role in growth: height velocityis markedly accelerated while the rate of skeletal
maturation is also increased with resultant fusion of
epiphyseal cartilages. Thus, puberty can be considered
as a growth-promoting event as well as the final height-
limiting process. This concept is illustrated by early
exposure to sex steroids such as occurs in central preco-
cious puberty or congenital adrenal hyperplasia. These
conditions accelerate growth but result in short adult
height (1-6).
The basic question addressed in this paper is how
hormonal changes at puberty and the age of their occur-
rence influence growth rate and adult height. This query
has practical implications including timing and dosage
of sex steroid replacement therapy in hypogonadal pa-
tients and the use of GnRH agonist therapy in patients
with precocious puberty or short stature. These issues
may have profound social import since numerous (mostly
* This work was supported in part by Grant 3.4574.87 from Belgian
Fonds de la Recherche Scientifique Medicale.
t To whom requests for reprints may be addressed.
uncharted) psychological aspects of adolescence may be
related to stature and the timing of sexual development.
The following sections will review 1) the hormonal
constituents of the pubertal spurt, 2) the auxological
parameters important for evaluating growth at puberty
and for predicting its importance for final height, 3) the
role of sex steroid dosage, 4) the role of age at onset of
puberty and, 5) some therapeutic implications.
II. The Hormonal Constituents of the Pubertal
Growth Spurt
Several hormonal factors may interact to determine
the pubertal growth spurt: GH, insulin-like growth factor
I (IGF-I), and sex steroids (androgens, estrogens) of
gonadal and adrenal origins. The permissive role of thy-
roid hormones and the interactions of insulin and nutri-
tion will not be discussed. The aim of this section is to
examine the respective roles of GH, IGF-I, and sex
steroids in eliciting the pubertal growth spurt.
A. Gonadal sex steroids
Growth-promoting effects independent of GH. In both
sexes, the role of gonadal steroids is obvious from the
remarkable acceleration of linear growth which occurs at
the time of sexual maturation (Fig. la) whether that
event is early, normal, or delayed (7). In the absence of
normal GH and IGF-I secretion, gonadal steroids have
limited growth-promoting effects (Fig. lb). This is sug-
gested by the subnormal increase of the growth rate in
hypopituitary boys treated with testosterone before GH
therapy was available (8).
Additional evidence of the effects of sex steroids in the
absence of GH action is obtained in patients with Laron
dwarfism (9) who present with high GH and very low
IGF-I and who attain an adult height of 110 to 140 cm.
Among eight of these patients followed longitudinally
throughout puberty (10), three girls did not show any
significant growth spurt. In contrast, in three boys and
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FlG. 1. Schematic representation of height in relation to age in normal
subjects (a), in the absence of normal GH or IGF-I secretion (b), and
in the absence of gonadal sex steroids (c). Dark portions of the curves
indicate the pubertal growth spurt.
puberty, height velocity increased to 6.5 cm/yr during
sexual maturation.
These observations (Fig. lb) suggest that sex steroids,
particularly androgens, may have a direct growth effect
independent of GH and IGF-I. This hypothesis is sup-
ported by recent observations of a stimulatory effect of
sex steroids on rabbit growth cartilage in vitro (11).
However, the concept of a GH-independent acceleration
of growth by sex steroids cannot be established in the
clinical situations described above since it is almost
impossible to demonstrate the complete absence of any
GH IGF-I effect in those patients. Nonetheless, the
acceleration of growth, if any, caused by sex steroids in
the absence of normal GH IGF-I is minimal when com-
pared to the normal pubertal spurt.
Sex specificity of gonadal steroid effects on growth. The
pubertal growth spurt is generally attributed to andro-
gens in boys and estrogens in girls. While, in females,
estradiol is clearly the sex steroid associated with puber-
tal growth, it is possible that, in males, the growth-
promoting effects of androgens are partly mediated
through their transformation into estrogens. This hy-
pothesis is supported by the following lines of evidence.
In Fig. 2 are illustrated the mean plasma levels of
estradiol and testosterone (calculated from Refs. 12-17)
in relation to the pubertal growth spurt in both sexes
(18). The interpretation of such data on plasma sex
steroid levels must be made with caution in the absence
of longitudinal observations of integrated night-time and
day-time levels in relation to bone age. Also, we do not
know the threshold plasma levels of estradiol and testos-
terone required for growth stimulation. Nonetheless, it
is interesting to note (Fig. 2) that a sharp increase in
testosterone secretion occurs quite late during puberty.
Therefore, at the time of maximal height velocity, plasma
testosterone levels in boys and girls are, respectively,
18% and 44% compared to concentrations achieved at
15-16 yr. In contrast, estradiol increases earlier than
testosterone in both sexes. At peak height velocity, es-
tradiol levels in boys and girls represent 75% and 72%,
respectively, of the concentration achieved at 15-16 yr.
In both sexes, aromatase has been found in several
extraglandular locations such as muscle and adipose
tissue (19) and it has been shown that only small
amounts of estrogens are produced by the testes. Most
of the estrogen is formed peripherally in male subjects
(20, 21). In addition to bone marrow (22), conversion of
androgen precursors into estrogens could occur in the
cartilage although we still lack evidence supporting such
hypothesis. An indirect argument for the role of estro-
gens in longitudinal bone growth in the male is the
presence of estrogen receptors in osteoblast-like cells (23,
24).
A physiological role for estrogens in the male pubertal
growth spurt is also supported by the correlation between
integrated GH concentrations and plasma estrogen con-
centrations (25) while no correlation is seen with testos-
terone (25-27). In addition, at puberty in both sexes, the
rising plasma levels of IGF-I are correlated to total
estradiol plasma levels (28) or free estradiol concentra-
tions but not with testosterone (25). However, it is pos-
sible that circadian and episodic fluctuations in plasma
sex steroid levels have biased those studies.
A more direct demonstration of a role for estrogens in
the male pubertal growth spurt has been provided by
Caruso-Nicoletti et al. (29). These authors have shown
that a 4-day infusion of estradiol to five prepubertal or
early pubertal boys results in a 2.6-, 2.0-, and 1.8-fold
increase in ulnar growth velocity when estradiol plasma
levels are 10, 16, and 96 pg/ml, respectively (29). Higher
concentrations of estradiol than those derived physiolog-
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FIG. 2. Relationship between the puber-
tal growth spurt and the plasma levels of
estradiol and testosterone in both sexes.
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growth effect (30). These data indicate that, in male
subjects, estrogens may have a biphasic effect similar to
that observed in girls.
A convincing demonstration of the role of endogenous
or synthetic estrogens in males has been provided by
Zachmann et al. in nine patients with the androgen
insensitivity syndrome (31). These phenotypic females
with an XY karyotype achieve a pubertal growth spurt
quantitatively and chronologically similar to normal
girls, with plasma estradiol concentrations within or
above the normal range for pubertal males. The obser-
vation of accelerated growth in prepubertal boys with
gynecomastia caused by increased testicular (32) or pe-
ripheral (33) aromatase activity also suggests a mediatory
role for estrogens in male growth. Finally, a contribution
of estrogens to pubertal growth in boys is suggested by
the significant reduction of height velocity to 6 cm/yr in
three patients with testotoxicosis treated using the aro-
matase inhibitor testolactone together with the antian-
drogen spironolactone while growth rate was 12 cm/yr
using spironolactone as a single therapy (58).
While several observations support the role of estradiol
in the male pubertal growth spurt, there is no clear
evidence of a physiological role for androgens in the
female pubertal growth spurt. Recently, Rosenfield (34)
showed that long-acting testosterone 28 mg/m2-month
given for 6 months to five Turner patients with pubertal
bone ages (10.6-12.8 yr) resulted in a 2-fold increase in
height velocity. This effect may have involved testoster-
one conversion into estradiol. However, it is likely that
androgens are themselves growth-promotors in girls
since treatment of patients with gonadal dysgenesis (35,
36) or hypopituitary girls (37) using nonaromatizable
androgenic steroids (oxandrolone and norethandrolone)
induces a significant acceleration of the growth rate.
The growth-promoting action of androgens and estro-
gens is at least partly explained by their stimulatory
effect on integrated GH concentrations (8, 26, 38). In
contrast, oxandrolone does not affect 24 h GH secretion
and plasma IGF-I levels (39). In a more recent study, a
significant but modest (+20%) increase in plasma IGF-I
levels has been reported after 3 months of oxandrolone
therapy in boys with constitutional delay of puberty (40).
Such an effect does not occur in prepubertal boys and
could be related to the increase in GH secretion or in
testosterone production at the beginning of puberty and
during its progression (41). However, a physiological role
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spurt cannot be inferred from the therapeutic effects of
oxandrolone.
Interactions of GH with sex steroid secretion. Some au-
thors have examined the question whether or not sex
steroid secretion is influenced by possible interaction of
GH with the pituitary-gonadal system. In hypopituitary
patients, the gonadotropin responses to synthetic GnRH
are not different before and during GH therapy (42).
This suggests that GH does not interact with FSH and
LH secretion at the pituitary level.
The interactions of GH at the gonadal level have been
investigated through sex steroid responses to human CG
(hCG). Early studies by Rivarola et al. (43) and by
Zachmann (44) in 1972 suggested a stimulatory effect of
GH on testosterone secretion after prolonged hCG ad-
ministration in three postpubertal patients. More re-
cently, in prepubertal hypopituitary boys, Zipf et al. (45)
and Maes et al. (46) did not observe any significant
change in testosterone responsiveness to HCG after,
respectively, 4 and 3 months of GH therapy. However,
in similar patients, Kulin et al. (47) found the testoster-
one response to hCG to increase after a longer period of
GH therapy ranging from 6 to 12 months. These latter
authors were unable to observe any GH-related change
in estradiol secretion induced by hCG in somatotropin-
deficient girls (48).
The decreased phallic size in some newborns with GH
deficiency (49) suggests a peripheral or intratesticular
interaction of GH with sex steroid production or action
during intrauterine life. There is no clinical data to
support a significant interaction at puberty. Also, evi-
dence is lacking of a major role for GH in priming
pituitary-gonadal maturation or in maintaining its func-
tional level in adults. However, rapid onset of puberty
has been observed within a few months after initiation
of hGH therapy in hypopituitary patients (50). We lack
detailed studies on pituitary-gonadal functions after
withdrawal of GH replacement therapy in patients with
isolated GH deficiency.
While the paracrine role of IGF-I in the gonads is well
established, its regulation by pituitary GH has not been
fully elucidated. Experimental data indicate that the
gonadotropins stimulate IGF-I production by cultured
porcine granulosa cells (51) and IGF-II gene expression
in human granulosa cells (52). In addition, testicular
IGF-I receptors may be induced by hCG and, conversely,
there is an up-regulation of hCG receptors by IGF-I (53).
Recent data suggest that GH may also be involved in the
control of ovarian IGF-I secretion (54).
B.GH
Growth effects of GH in the absence of sex steroids. In
patients with sex steroid deficiency and normal GH
secretion (Fig. lc), no pubertal growth spurt occurs.
Patients with congenital hypogonadism (anorchia or
Kallman's syndrome) have a normal pattern of prepu-
bertal growth (55). However, no obvious pubertal growth
spurt occurs in GH-treated boys with gonadotropin de-
ficiency unless sex steroids are administered (56, 57).
A so-called "normal" adult height is attained by hy-
pogonadal patients with isolated gonadotropin deficiency
not treated with sex steroids before epiphyseal fusion
(58, 59). This indicates that, on the whole, adult stature
is not affected by the absence of sex steroids. However,
body proportions are not normal in those patients. This
is because the adolescent spurt in sitting height is pre-
dominantly controlled by sex steroids and relatively in-
dependent of GH, while the spurt of legs is GH-depend-
ent (56). Therefore, the apparently normal expression of
growth potential in the absence of sex steroids results
from an excess in leg growth relative to growth of the
trunk.
Interactions of sex steroids with GH secretion. Numerous
authors have shown that sex steroids modulate GH se-
cretion. While early studies were focused on GH response
to pharmacological tests, more recent observations have
examined the amplitude, the frequency, and the inte-
grated concentrations of intermittent GH secretion.
An early study of testosterone effect on GH response
to insulin-induced hypoglycemia or arginine in boys with
constitutional delay of puberty was reported by Martin
et al. in 1968 (60). These authors confirmed their earlier
observation by showing that 21 of 22 boys, with consti-
tutional delay of puberty and a subnormal GH respon-
siveness, normalized their GH levels after a 5-day course
of testosterone propionate therapy, 25 mg/day (61). In 4
patients with anorchia, Illig and Prader (62) found an
impaired GH response to insulin-induced hypoglycemia
which was normalized by a 2- to 3-month testosterone
therapy while the same treatment did not affect GH
responsiveness in a GH-deficient patient.
In a cohort of 105 patients with constitutional growth
delay, Gourmelen et al. (63) reported that 23% had a
reduced GH response to ornithine or insulin-induced
hypoglycemia. After spontaneous puberty was begun, GH
response was normalized, confirming early observations
on the increase of GH response to arginine- or insulin-
induced hypoglycemia during normal puberty (64, 65).
Estrogens are also effective in increasing GH secretion
after provocative stimuli as shown by studies on the
effects of short-term administration of relatively high
estrogen doses (66-71).
The study of integrated GH concentrations has pro-
vided information on the physiological interactions be-
tween sex steroids and GH. In several studies, integrated
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subjects of both sexes than those seen before puberty
and during adulthood (25, 38, 72-75). In girls with central
precocious puberty, integrated concentrations of GH are
increased 1.5 times over prepubertal values (76) and
reduced to 0.5 times the pretreatment level after 6
months of treatment with a GnRH agonist (77). In boys
with constitutional delay of puberty (39, 78) and in males
with hypogonadotropic hypogonadism (79), integrated
GH concentrations are increased up to 4.3 times after
chronic testosterone therapy.
During spontaneous puberty, the priming effect of sex
steroids on integrated GH concentrations is dependent
on an increased amplitude of GH secretory episodes while
frequency is not affected (25, 80). In addition, testoster-
one administration to patients with delayed puberty or
hypogonadism results in a 2.1- to 3-fold increase of GH
pulse amplitude whereas pulse frequency is unchanged
(39, 79, 80).
Some observations do not corroborate a stimulatory
effect of sex steroids on GH secretion. Spiliotis et al. (81)
did not observe any significant change in integrated
concentrations of GH between prepuberty and puberty,
in accordance with a previous report by Thompson et al.
(26) and with some of the observations by Drop et al.
(82). These different results may be explained by the
heterogeneity of patients studied; that is, the administra-
tion of sex steroids or the occurrence of spontaneous
puberty will increase GH secretion in patients with con-
stitutional delay of puberty but not in those having any
form of GH deficiency.
Contribution of GH to the pubertal growth spurt. In pa-
tients with isolated GH deficiency, the pubertal growth
spurt is severely reduced, which contributes in part to
the shortened adult stature (83, 84). This observation
unequivocally establishes GH as a prerequisite to the
growth spurt. However, the threshold level of GH secre-
tion required to obtain a pubertal spurt may be low since
a moderate but significant acceleration of the growth
rate (6.8 cm/yr) is seen in girls with central precocious
puberty and deficient GH response (<5 /ig/ml) to pro-
vocative stimuli (114). Also, it is unclear whether the sex
steroid-induced rise in GH secretion is a requirement for
achieving the spurt. In fact, a pubertal growth spurt
occurs under constant GH replacement in hypopituitary
patients (56, 57, 85-90). However, in such individuals,
the mean peak height velocity during spontaneous and
testosterone-induced puberty is 7.6 and 7.3 cm, respec-
tively, a consistently lower gain than the average peak
of 10.3 cm/yr (91, 92) found in normal boys. Noteworthy,
the peak height velocity is physiologically lower in late
maturers (18) who are close to patients with untreated
isolated GH deficiency in terms of timing of onset of
puberty. Also, the lower peak height velocity in those
patients may result from the nonphysiological schedule
of GH administration which was 3 times a week in the
above studies.
An alternative explanation is the absence of a puberty-
related increase in GH dosage. This hypothesis is not
supported by the data of Job et al. (93) in patients with
isolated GH deficiency. These authors obtained mean
total pubertal height gains of 21.0 and 14.3 cm in hypo-
pituitary boys and girls, respectively, while the normal
spurts are 28 and 25 cm. They found no relationship
between pubertal height gain and hGH dosage varying
between 12 and 26 IU/kg-yr. As pointed out by Job et
al., these variations of GH dosage may be too small since
there is an exponential relationship between growth rate
and hGH dosage (94, 95). Still, a critical factor is the
discrepancy between GH administration 3 times a week
and physiological GH secretory pulses several times a
day since the so-called replacement doses of GH are well
above the normal production rate of GH.
C. Somatomedin C/IGF-I
Plasma IGF-I: origin and role in growth. Since Salmon
and Daughaday (96) described the growth-promoting
action of GH as dependent on an intermediate factor
identified later as somatomedin C or IGF-I, evidence has
accumulated to establish the GH-dependent production
and release of IGF-I as a fundamental mechanism in the
endocrine control of growth (97-99). Studies attempting
to localize the site of IGF-I production failed to identify
a major and exclusive source for the pool of IGF-I cir-
culating in plasma, although it is generally agreed that,
in man, at least half the circulating IGF-I comes from
the liver. The existence of different IGF-I sources is
consistent with the observation of IGF production by
several tissues from human fetuses (100, 101) and adult
fibroblasts (102,103), indicating its possible paracrine or
autocrine role as well as endocrine function.
In the rat, a direct action of GH on bone growth has
been shown by Isaksson et al. (104). This effect appears
to involve IGF-I production locally by the growth plate
under the control of GH as shown recently in that species
(105). To date, it is unclear how and to what extent
circulating IGF-I and IGF-I synthesized locally in the
cartilage contribute to skeletal growth. Other important
methodological and physiological questions arise from
the existence of certain IGF-I binding proteins which
also make interpretation of IGF-I circulating levels dif-
ficult. The unsaturated IGF-I binding protein level (106)
and its radioimmunoassayable low molecular weight
form (107) are high in conditions associated with low
plasma IGF-I levels, such as hypopituitarism, while the
binding protein is lowered by a treatment using GH
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that IGF-I may regulate negatively the production of
some fractions of its binding protein while others are
positively regulated.
In hypopituitary or short-stature patients, growth re-
sponse to GH therapy is not correlated with plasma IGF-
I levels (108-110). A similar dissociation between growth
rate and plasma IGF-I levels is found in late normal
puberty after the growth spurt (28, 111, 112) and during
GnRH agonist therapy in central precocious puberty (77,
113), while before therapy, the growth rate and the
plasma IGF-I levels are positively correlated. (114).
These results are consistent with local production of
IGF-I in the cartilage. In those cases, plasma levels of
IGF-I represent more likely an index of total production,
not necessarily a requirement for longitudinal growth.
Interactions of sex steroids with IGF-I. At puberty, there
is a characteristic rise in plasma concentrations of IGF-
I (28, 115-117). Detailed studies of this phenomenon
have shown that this increase in IGF-I plasma levels
occurs 1 yr earlier in girls than in boys (112) and is
correlated to plasma estradiol levels in both sexes (28,
31). In children with central precocious puberty, IGF-I
shows a premature rise (76, 77) which can also be induced
by treating hypogonadal patients with androgens (39, 79,
118) as well as with estrogens (119-121). Thus, experi-
mental and clinical evidence indicates that increased sex
steroid secretion is associated with stimulation of GH
and IGF-I and accelerated rates of growth and of bone
maturation (Table 1).
The growth-promoting effect of sex steroids, however,
does not necessarily require an increase in plasma con-
centrations of IGF-I. In hypopituitary boys under GH
replacement therapy at a constant dosage, testosterone
accelerates growth without concomitant stimulation of
TABLE 1. Interactions between sex steroids, IGF-I, and growth in





























plasma IGF-I concentrations (111, 118, 122). A similar
finding is present in patients with gonadal dysgenesis
treated with low-dose estrogens (120, 123, 124). In these
conditions and in others such as the late stages of normal
puberty and high-dose estrogen treatment in tall girls,
variations of plasma IGF-I levels do not parallel the
changes in plasma sex steroid concentrations (Table 1).
Some of those discrepancies may be explained by a dose-
related biphasic effect of estrogens (28, 120).
In African pygmies, an illustration of the role of IGF-
I at puberty has been proposed by Merimee et al. (125,
126). They reported that these subjects develop normal
sex characteristics and pubertal plasma levels of sex
steroids but show no pubertal growth spurt and end up
with a mean adult stature of 144.0 cm. The proposed
explanation is that plasma levels of IGF-I that are nor-
mal before puberty only increase to 35-49% of the con-
centrations seen during normal puberty. In fact, careful
examination of the original growth data (127) indicates
that linear growth accelerates at puberty in pygmies; the
apparent absence of a pubertal spurt results quite likely
from the use of pooled cross-sectional observations (Tan-
ner J., personal communication). Reevaluation of auxo-
logical data will be necessary for correlating IGF-I levels
and quantitated parameters of pubertal growth.
Are the effects of sex steroids on IGF-I secretion
mediated by GH? Such a mechanism is strongly sug-
gested by the absence of changes in IGF-I secretion after
sex steroid administration to hypopituitary patients un-
der a constant regimen of GH therapy (111, 118, 122).
Also, observations during normal or precocious puberty
show a direct relationship between the increase of IGF-
I and integrated GH concentrations (25, 76), both
changes being reversed during GnRH agonist therapy
(77).
Some stimulatory effects of sex steroids on IGF-I may
be independent of GH since increased IGF-I levels with
unchanged GH secretion have been observed during low
dose estrogen or oxandrolone therapy in gonadal dysge-
nesis patients (36, 128). The unchanged plasma IGF-I
levels reported by others during similar treatments (35,
123, 124) do not exclude a local stimulation of IGF-I by
sex steroids in the cartilage. In other conditions, a dis-
sociation between IGF-I and GH secretion is observed.
In acromegalic patients or in adolescent girls with tall
stature, estrogen therapy at relatively high dosages does
not affect IGF-I levels (70) or reduces IGF-I concentra-
tions (66, 68, 69, 129) while GH secretion is elevated in
those conditions.
D. Adrenal sex steroids
A possible role for adrenal androgens in the control of
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men and women with untreated congenital adrenal hy-
perplasia. In this condition, high testosterone levels are
well established in addition to increased A4-androstene-
dione and dehydroepiandrosterone (DHEA) secretion.
From the data of Thamdrup (1), Styne et al. (3), Jones-
Klingensmith et al. (4), Urban et al. (5), and Di Martino-
Nardi et al. (6), mean adult height observed in 9 male
patients and 39 female patients never treated before
adulthood was 153.8 cm and 150.6 cm, respectively. This
is an obvious, but not striking, reduction in adult stature,
given the prolonged period of androgen excess.
A stimulatory role for adrenal androgens in the control
of growth in normal children was suggested by the con-
comitant onset of adrenarche (12, 13) and an increase in
height velocity observed in prepubertal children around
7-9 yr of age (130). In contrast, in hypopituitary boys
and girls, or other patients with absent adrenarche, phys-
iological replacement using long-acting injectable DHEA
or its short-acting oral form (DHEA-sulfate) for 1 to 2
yr failed to elicit any significant increase in height veloc-
ity (131-133). Thus, an excess of adrenal androgens and
testosterone has been shown to accelerate linear growth
and bone maturation. Although these hormones cause
premature growth arrest and short stature in pathologi-
cal conditions, there is no evidence for a physiological
role of adrenal androgens in the control of normal
growth.1
E. Summary: hormonal constituents of the pubertal
growth spurt
In Fig. 3 are represented the three pathways of sex
steroid interaction with growth at puberty.
1. Sex steroids may themselves have a growth-promot-
ing action independent of GH and IGF-I, but this seems
to be a rather minor contribution to the pubertal growth
spurt.
2. The major mechanism is the increased amplitude of
GH secretory episodes in the presence of sex steroids,
estradiol being the putative mediator of this effect. GH
in turn stimulates IGF-I production, accounting for or
reflecting the increased growth rate.
3. In the absence of GH increase, another possible
mechanism is the direct interaction of sex steroids with
IGF-I secretion. As detailed in the following section, this
effect is biphasic for estrogens since only low doses are





1 Editor's comment: The failure of DHEA administration to increase
height velocity does not exclude the possibility that adrenal androstene-
dione may promote prepubertal bone growth by conversion to estrogen.
DHEA is a much less efficient precursor of peripheral estrogen synthe-
sis than is androstenedione (see Ref. 183).
SEX
STEROIDS
FIG. 3. Schematic representation of the hormonal mechanisms possi-
bly involved in the pubertal growth spurt.
III. The Auxological Parameters Used to
Evaluate Growth at Puberty and to Predict its
Importance for Final Height
A. Pubertal growth
It is interesting to examine the adequacy of the auxo-
logical parameters that we use to evaluate pubertal
growth. Peak height velocity is a commonly used index
of pubertal growth. It can be optimally calculated by
fitting the height velocity curve when a sufficient amount
of data have been obtained. In physiological variants of
growth, differences in peak height velocity are consistent
with differences in total pubertal height gain. This is
because physiological increase or reduction in amplitude
of peak height velocity is associated with parallel increase
or reduction in duration of the growth spurt (91). How-
ever, this is no longer true in severely delayed puberty
such as in hypopituitarism (134). In these patients, ad-
vancement in bone age at onset of puberty results in a
prominent reduction in duration of puberty while the
amplitude of their growth spurt is less affected. There-
fore, they show a 57% decrease in total pubertal height
gain between 11.0 and 15.0 yr at onset of puberty while
peak height velocity is only reduced by 22% at the same
time (Fig. 4).
Thus* the evaluation of pubertal growth in pathological
situations should be performed using total pubertal
height gain rather than peak height velocity or growth
rate which are calculated after a follow-up of 1 or 2 yr
during puberty. In fact, peak height velocity and growth
rate are used because most studies are performed before
final height has been attained. While such studies pro-
vide some indication of the growth response to sex ste-
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I
FIG. 4. Peak height velocity (left panel)
and total pubertal height gain (right
panel) in relation to bone age at onset of
puberty in 22 hypopituitary boys studied
during spontaneous puberty (A) or tes-
tosterone therapy (•). Individual data
are shown in the lower panels. The upper
panels represent the slopes of the corre-
lations as a percentage of the values seen
at 11.0 yr of bone age. The upper part of
the figure illustrates schematically the
differences in peak height velocity and
total pubertal height gain. [Reproduced
with permission from J. P. Bourguignon:
Ada Pediatr Scand [Suppl] 343, 1988
(134).]
30
15 yr ;; 12 15 yr
BONE AGE AT ONSET OF PUBERTY
from the growth rate seen immediately after onset of
puberty.
B. Final height predictions
Obviously, final height cannot be determined until
epiphyseal cartilages have closed. Since it takes such a
long time to attain final height, in the clinical setting we
attempt to predict the ultimate stature of patients in
order to evaluate the likely effects of therapeutic modal-
ities. For instance, in patients with central precocious
puberty treated with GnRH agonists, there are no data
available on ultimate height so that, to date, only predic-
tions can be used.
Some auxological parameters studied in relation to
final height are summarized in Table 2. Adult stature
represents the sum of height gains obtained at different
periods of life. Puberty is the last important period of
life for height gain since postpubertal growth is minimal.
At each growth period, including puberty, height gain is
the product of two parameters: height velocity and du-
ration of growth. For a given period of growth, height
velocity is the height increment (Aheight) over Achron-
ological age. During that period, duration of growth is a
direct function of chronological age but inversely related
to Abone age, which is the rate of bone maturation. Thus,
height gain during a given period of life is directly related
to Aheight and inversely related to Abone age. Conse-
quently adult stature is also a direct function of Aheight
and an inverse function of Abone age.
According to the statements above, predictive evalua-
tion of the effects of any endocrine condition or therapy
TABLE 2. Auxological parameters used to evaluate the relative influ-
ences of growth rate and age on adult stature
Prenatal length gain
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on ultimate height must rely on studies of the rate of
linear growth (Aheight) vs. the rate of bone maturation
(Abone age). Before adult stature is attained, the three
following parameters are commonly used in order to
relate growth rate and bone maturation rate (Table 2):
the ratio of Aheight age to Abone age (AHA/ABA), the
Apredicted adult height and the AStandard Deviation
Score (SDS) of height for bone age. These three param-
eters are all dependent on the estimation of bone age
which includes errors inherent to the reading of the x-
ray film and the characteristics of the children used as
controls. These errors restrict the significance of any
method of final height prediction. In addition, the degree
of shortness may bias the calculations used to estimate
the ratio between A height and A bone age. Such biasing
effects can be shown using theoretical growth data (Fig.
5).
In Fig. 5a are illustrated theoretical data of height in
relation to bone age in three subjects. These subjects
differ only by their height at the beginning of a 1 yr
study (140, 155, and 170 cm) while they show the same
height gain of 5 cm and the same increase in bone age
from 14.0 to 15.0 yr (ABA = 1.0 yr) during the study. In
Fig. 5b, it is shown how height ages and AHA are calcu-
lated using the heights of the three subjects and the 50th
centile curve of height from the standards of Tanner and
Davies (18). Since the 50th centile curve is not rectilinear
but changes with age, particularly at puberty, the calcu-
lation of height age is markedly influenced by the degree
of shortness which is different among the three subjects.
This is why they show AHA varying between 0.5 and 1.4
yr while their ABA is 1.0 yr. Thus, calculation of AHA/
ABA ratio is biased by the degree of short stature which
affects AHA. Because of such biasing effect, AHA/ABA
does not represent a suitable index for relating growth
rate and bone maturation rate.
Calculation of predicted adult height provides another
means of integrating the rate of growth and the rate of
bone maturation. This calculation can be done using
tables or equations based on sex, height, and bone age
which are the main data used to predict final height. In
a previous study by Zachmann et al. (135) comparing
different methods of adult height prediction, it was con-
cluded that the method of Bayley-Pinneau (136) using
bone ages rated according to Greulich and Pyle (137)
provided the most consistent predictions. Final height
predictions are less accurate in patients showing marked
deviations from the range of physiological variations in
height or marked differences between bone age and
chronological age. In addition, height predictions may be
biased by the degree of shortness, as shown in Fig. 5c.
Using the equations of Tanner et al. (138), we have
calculated predicted adult heights in the three subjects
studied for 1 yr. While those subjects had identical bone
ages, height gains, and ABA, they had different changes
in predicted adult heights. The tallest one would gain 0.8
cm while the shortest would lose 1.9 cm. This represents
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FlG. 5. Influence of the degree of short stature on three methods used to evaluate growth rate in relation to bone maturation rate, a) Height in
relation to bone age is shown in three subjects with identical bone ages, growth rates, and bone maturation rates but different degree of short
stature. Curve 50 represents the 50th centile of height for average maturers according to Tanner and Davies (18). b) The ratios Aheight age/A
bone age have been calculated for the three subjects. The broken lines indicate how the height ages are calculated. ABone age is 1 yr in the three
subjects, c) Predicted adult heights [TW mark II equations, (138)] have been calculated at 14.0 and 15.0 yr of bone age for each subject. The
numbers indicate the differences between the two predictions calculated for each of the three subjects, d) SDS of height for bone age have been
calculated at 14.0 and 15.0 yr of bone age in the three subjects, with reference to height for bone age at the 50th centile as shown by the broken
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biasing effect of the degree of short stature on the cal-
culation of predicted adult height may increase with the
length of the study period.
The growth rate can also be related to the rate of bone
maturation by calculating the standard deviation score
(SDS or Z score) of height for bone age. This is the
difference between a patient's height (x) and mean nor-
mal height for the same bone age (x), divided by the SD
of height for that bone age. Thus, SDS = (x - x)/SD.
Using this calculation, it is shown in Fig. 5d that the
same ASDS of height for BA (-0.23 SD) is found in the
three subjects studied with different degree of short
stature. This indicates that ASDS of height for BA is
not biased by the degree of short stature. However, SDS
of height for bone age still involves errors inherent to
bone age estimation. In addition, the standard deviations
of height for chronological age are used improperly for
relating height to bone age since there is no available
data base of height for bone age.
Thus, when pubertal growth is studied, the important
parameter is total pubertal height gain which is the
product of mean height velocity and duration of pubertal
growth. When we predict how adult stature can be af-
fected by therapies inducing or delaying puberty, height
gain and ABA during therapy are the two major factors.
In order to relate these two factors, methods using height
age are not appropriate. The calculation of adult height
predictions or SDS of height for bone age should be
considered carefully. Further recommendations should
rely on retrospective studies of different methods for
adult height prediction in specific groups of subjects or
patients having attained adult stature. It is likely that
the methodological errors would be minimized using
specific prediction methods for each type of growth dis-
order.
IV. Role of Sex Steroid Dosage
Factors such as age at onset of sex steroid action and
dosage of sex steroids may determine differences in the
rates of growth and bone maturation during pubertal
growth. Those two key factors are particularly important
in the therapeutic management of patients with disorders
of puberty. In the following sections, the role of sex
steroid dosage and age at onset of puberty on pubertal
growth, bone maturation rate, and final height will be
examined in both sexes.
A. Role of estrogens
Effects of estrogen dosage on pubertal growth. In hypopi-
tuitary girls, very limited studies have been published on
growth during estrogen therapy (87,139,140). The major
data bearing on the importance of estrogen dosage for
growth response have been obtained in patients with
gonadal dysgenesis {vide infra)
In 1974, Rosenfield and Fang (119) reported on the
growth response to low-dose estrogen in subjects with
gonadal dysgenesis. In contrast, high doses (equivalent
to more than 1 /ug/kg-day of ethinyl-estradiol), had been
shown not to affect the growth rate (141). In a short-
term study using different estrogen doses, Ross et al.
(120) observed a 2-fold increase in the growth rate of the
ulna by ethinyl-estradiol 0.1 /ig/kg-day. Higher dosages
of 0.4 and 0.8 /xg/kg-day were not effective on bone
length, indicating the biphasic nature of estrogen effects
upon growth. Although this study only considered the
growth of the limbs, growth of the trunk is equally
important to the pubertal spurt. More recently, in a
double-blind, placebo-controlled study using 0.1 yu.g/kg-
day ethinyl-estradiol for 6 months, the same group has
shown a 70%-increase in height velocity induced by
estrogens (123).
In Fig. 6, the results from 8 available studies on estro-
gen effects in patients with gonadal dysgenesis are com-
piled (119, 121, 123, 124, 142-145). The data are plotted
in relation to bone age at onset of estrogen therapy,
which is variable over a range of 6 yr between 8.1 yr
(145) and 13.8 yr (143). In all these studies, bone ages
were rated according to Greulich and Pyle (137) except
for patients starting treatment at 13.0 yr of bone age in
whom calculations were made according to the method
of Tanner et al. (138). In order to include the patients
studied by Ross et al. (123), mean bone age was arbitrarily
considered to be delayed 1.5 yr below their mean chron-
ological age, based on the findings of Martinez et al.
(124). While weight was not stated by the authors, body
weight-related doses of estrogen were calculated for a 40-
kg patient (119,141-143, 145). The following drug equiv-
alents were used in this compilation: 10 /u,g/day ethinyl-
estradiol (EE) = 1 mg/day 17/3-estradiol (given orally) =
2 mg/month of long-acting estradiol ester (given im) =
0.3 mg/day conjugated estrogens (given orally).
The interpretation of the effects of estrogen dosage
upon growth in patients with gonadal dysgenesis is dif-
ficult since available information involves differences in
estrogen dose and differences in age at onset of admin-
istration. When these studies are reviewed (Fig. 6), the
dose of estrogen used does not seem to play a major role
in determining the immediate growth response. This is
quite clear in the 4 groups of patients beginning treat-
ment between 11.1 and 12.1 yr of bone age (121, 142,
143, 145). They exhibit similar growth rates despite the
use of very different estrogen dosages. However, it is still
possible that estrogen dosage will influence the total
pubertal height gain since the growth rates observed
during the first year of estrogen therapy may not parallel
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FIG. 6. In patients with gonadal dysgenesis, mean height velocity
(H.V.) before therapy {upper panel), mean height velocity during the
first year of estrogen therapy {middle panel), and the ranges of daily
estrogen dosage (lower panel) are plotted in relation to mean bone age
at onset of treatment. (Data compiled from Refs. 119, 121, 123, 124,
142-145). In the bars, the numbers of patients studied are indicated,
and the original references for the data used are given between paren-
theses.
Effects of estrogen dosage on the rate of bone maturation.
In patients with gonadal dysgenesis and, by inference, in
normal girls, the dose of estrogen may be critical for the
rate of bone maturation. In several studies of Turner's
patients compiled in Fig. 7, left panel (119, 123, 124, 142,
145), ABA/AC A has been estimated according to Greu-
lich and Pyle (137). In order to include the data from
Ross et al. (123) in this compilation, bone age at onset
of estrogen therapy was assumed to be 8.5 yr (1.5 yr
below mean chronological age). As shown in Fig. 7, in
patients who began estrogen therapy before a mean bone
age of 10 yr, Kastrup et al. (145) observed a mean ABA/
ACA of 2.92 using a daily dose of ethinyl-estradiol rang-
ing between 0.1 and 0.4 Mg/kg. In contrast, using a lower
dose of 0.1 ^g/kg, Ross et al. (123) and Martinez et al.
(124) found ABA/ACA to be 0.92 and 1.65, respectively.
Effects of estrogen dosage on final height. To date, we
lack information about final height in relation to the
dosage of estrogens used as replacement therapy. In tall
girls, treatment with high doses of estrogens has been
shown to induce an acceleration in bone maturation
accounting for the decrease in ultimate height (66, 129,
146-148). This indicates that the biphasic effect of estro-
gens on the growth rate differs from the consistent
acceleration in bone maturation rate seen with the ad-
ministration of high doses (>0.1 mg/day) of ethinyl-
estradiol (149).
B. Role of androgens
Effects of androgen dosage on pubertal growth. In hypo-
pituitary boys, pubertal growth has been studied during
therapy with testosterone enanthate at different dosages
ranging between 100 and 250 mg/month (57, 85-87, 89,
90). In these studies (Fig. 8), treatment was started at
similar bone ages (12.8-14.0 yr). In addition, hGH ther-
apy was given at similar doses varying between 12 and
19.5 IU/week. While the different dosages of testosterone
resulted in minimal differences in peak height velocity,
between 6.3 and 8.0 cm/yr, the total pubertal height gain
was 2-fold higher using testosterone 100 mg/month com-
pared to using 250 mg/month (Fig. 8). This illustrates
not only the importance of testosterone dosage but also
the discrepancy between peak height velocity and total
pubertal height gain which has been described above.
A monthly injection of 100 mg testosterone enanthate,
is, in fact, too high for beginning hormone replacement
therapy (86). As shown in Fig. 9, GH-treated hypopitui-
tary patients who were given testosterone enanthate 100
mg/month revealed an earlier occurrence of stages 4 and
5 of genital development and an earlier achievement of
peak height velocity than hypopituitary boys developing
spontaneous puberty. This is consistent with plasma
testosterone levels which were higher during therapy
than during the first year of spontaneous puberty. It is
to be noted that the testosterone levels measured the
first week after the injection would have been even
higher.
Effects of androgen dosage on the rate of bone maturation.
During normal puberty, sex steroids may accelerate the
bone maturation rate. In boys Buckler (150) reported an
acceleration of bone maturation rate (ABA/ACA = 1.73)
concomitant with the peak height velocity. In hypopitui-
tary boys, dosage is also important for the effect of
testosterone on bone maturation. As shown in Fig. 8
{lower panel), ABA/ACA is less in patients treated with
testosterone enanthate 100 or 150 mg/month (57, 86)
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FIG. 7. The velocity in bone maturation (ABA/ACA) during treatment for induction or inhibition of sexual maturation is plotted in relation to
pretreatment bone age in different conditions: Turner patients during the first year of estrogen therapy (mean ± 1 SD calculated from Refs. 119,
123, 124, 142, and 145), (left panel); hGH-treated hypopituitary boys during supplementation with testosterone enanthate 100 mg/month for a
mean period of 2.7 yr [Reproduced with permission from J. P. Bourguignon et a/.: J Clin Endocrinol Metab 63:376, 1986 (86)], (middle panel); and
patients with central precocious puberty during the first year of treatment with buserelin, a GnRH agonist [Reproduced with permission from J.
P. Bourguignon et a/.: Ada Endocrinol (Copenh) 116:519, 1987 (155)], right panel. The number of Turner patients (left panel) is indicated in the
bars, and the references are cited in parentheses over the error limits.
Effects of androgen dosage on final height. In excessively
tall boys, long acting esters of testosterone given at a
high dosage of 500 mg twice a month result in a reduction
of final height us. adult height predicted before therapy
(151).
In hypopituitary boys who have been treated with
replacement doses of long acting testosterone usually
varying between 100 and 250 mg/month, it is difficult to
draw conclusions since several other important factors
such as age at onset of GH therapy and height at onset
of puberty may interact. In addition, the amount of
testosterone given to initiate therapy and the duration
of low dose treatment may play some role. Nonetheless,
data on adult stature obtained in different studies (85-
87, 89, 90) are in a relatively narrow range between —1.4
and —2.0 SD, suggesting that, in the range of doses used
(100-250 mg/month), there is no major effect of andro-
gen dosage on final height. Lower doses (25 or 50 mg/
month) maintained for the first year of treatment require
further study.
V. Role of Age at Onset of Puberty
Bone age represents an index of maturation which is
more closely related to growth than chronological age.
This is particularly obvious for patients who deviate
significantly from the normal tempo of growth and pu-
berty. In some instances, data on bone age may not be
available. Therefore, puberty and final height have also
been studied in relation to chronological age in male
subjects.
A. Girls
Effects of age at onset of female puberty on pubertal
growth. In hypopituitary girls, there is a possible role for
bone age in determining growth response to sex steroids.
In GH-treated girls starting estrogen therapy at mean
bone ages of 12.3 (139) and 13.2 yr (87), total pubertal
height gain is minimal (2 and 5.2 cm, respectively). Such
a low response of growth to estrogens has been confirmed
by Rolland et al. (140). In contrast, during spontaneous
puberty in GH-treated girls, total pubertal height gains
of 22 (87) and 23 cm (85) have been reported. These
differences in pubertal growth may relate to the bone age
at onset of spontaneous breast development (10.1 and
10.4 yr, respectively) compared to the age at onset of
estrogen therapy (12.3-13.2 yr).
Interesting information on the role of age on growth
response to estrogens has also been obtained in patients
with variants of gonadal dysgenesis. These individuals
do not represent the most appropriate model for sex
steroid effects on growth since there is impaired growth
during intrauterine life and during the prepubertal period
as well (152, 153). In addition, relatively high dosages of
GH are required to improve growth in Turner patients
(35,154).
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FlG. 8. Effects of a 0.5 to 2-yr course of testosterone therapy at
different doses on peak height velocity, total pubertal height gain, and
the rate of bone maturation (ABA/ACA) in hypopituitary boys. The
numbers in parentheses indicate the references. When available, bone
age at onset of testosterone therapy is indicated at the top of the figure.
with observations in untreated patients (152, 153), there
is a progressive decline of pretreatment height velocity
with age. Growth response during the first year of estro-
gen therapy (Fig. 6, middle panel) follows a similar age-
related reduction from 7.5 to 1.7 cm/yr. These findings
not only reflect the impact of pretreatment height veloc-
ity but also a decrease in responsiveness to estrogens
with age. In fact, the increase in height velocity over
pretreatment level was 60-113% before 10 yr of bone
age, 40-89% between 11 and 12 yr, and 21-46% between
13 and 14 yr.
Effects of age at onset of female puberty on the rate of
bone maturation during puberty. As shown in Fig. 7 (left
panel), during estrogen administration to patients with
gonadal dysgenesis, ABA/ACA tends to decrease in re-
lation to bone age at onset of therapy. Such a negative
relationship between ABA/ACA calculated according to
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FIG. 9. Pubertal development in GH-treated boys with normal gonad-
otropin secretion (left panels, n = 8) or with gonadotropin deficiency
(right panels, n = 14). Mean (±1 SD) score of genital development
(stages 4 and 5 according to Tanner), mean height velocity, and mean
plasma testosterone levels are shown in relation to time before and
during spontaneous puberty or testosterone therapy (testosterone en-
anthate 100 mg/month im). In testosterone-treated patients, blood for
testosterone measurement was obtained about 2 weeks after the last
injection of testosterone enanthate 100 mg. [Adapted with permission
from J. P. Bourguignon et al.: J Clin Endocrinol Metab 63:376, 1986
(86).]
patients with central precocious puberty (155) during
treatment with buserelin, a superagonist of GnRH (Fig.
7, right panel). For patients with precocious puberty, a
similar correlation has been found by Boepple et al. (156)
in girls treated with the [D-Trp6-Pro9-iV-ethylamide]-
GnRH analog.
Effects of age at onset of female puberty on final height.
While the reduction of adult stature in girls with early
exposure to estrogens is well established (1, 2), the effects
of late onset of estrogen therapy on final height are
unknown. This is partly explained by the low incidence
of conditions such as hypogonadotropic hypogonadism
or panhypopituitarism in females as compared to males.
This question deserves further study, particularly be-
cause the growth response to estrogens in girls seems to
be more age-dependent than the response to androgens
in boys [vide infra).
B. Boys
Effects of age at onset of male puberty on pubertal growth.
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pubertal height gain as indicated by the early observa-
tions of Boas (157). Several authors have confirmed this
relationship using peak height velocity (91, 92) or puber-
tal height gain (158) as the index of pubertal growth.
In hypopituitary boys, the role of bone age on growth
response to testosterone therapy has been known from
early data obtained using high doses of androgens (tes-
tosterone enanthate > 300 mg/m2-month) before hGH
treatment was available. After initiating testosterone
administration at a mean bone age of 13.5 yr, Aynsley-
Green et al. (57) obtained a maximal growth rate of 5.5
cm/yr during a 1.9 yr period of treatment. This obser-
vation is similar to the 5.2 cm/yr reported by Zachmann
and Prader (159) under the same conditions. In contrast,
when testosterone was started at 8.5 yr of mean bone
age, Blizzard et al. (8) obtained a more pronounced
increase in height velocity, up to 8.5 cm/yr (recalculated
from their data).
As shown in Fig. 10, the parameters of pubertal growth
exhibit a similar pattern of variation in relation to bone
age in hypopituitary boys and in relation to chronological
age in groups of subjects or patients beginning puberty
at different ages between infancy and early 20s (134).
The total pubertal height gain is negatively related to
age at onset of puberty. It can be seen in Fig. 10 that the
age-related decrease in total pubertal height gain is ex-
plained by a reduction in duration of pubertal growth. In
contrast, there are only minor differences in mean pu-
bertal growth rate which has been calculated as the total
height gain divided by the duration of puberty.
Effects of age at onset of male puberty on the rate of bone
maturation during puberty. During testosterone therapy
in GH-treated hypopituitary boys (Fig. 7, middle panel),
as well as during spontaneous puberty in boys with
isolated GH deficiency (86), the rate of skeletal matura-
tion decreases with age at onset of puberty. As a matter
of fact, when referred to an average normal ABA/ACA
of 1, patients starting puberty at an early bone age have
a rapid rate of bone maturation during puberty while
those entering puberty at a late bone age have a slow
rate of bone maturation during puberty. The question
arises whether or not those age-related differences in
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FIG. 10. Total pubertal height gain, duration of pubertal growth, and mean pubertal growth rate in relation to age at onset of puberty. Left panels,
Individual data of hypopituitary boys (A, spontaneous puberty, #, testosterone-induced puberty) in relation to bone age. Right panels, data
compiled from the literature and studied in relation to chronological age; groups B and C: boys with idiopathic precocious puberty (1, 2); groups
D, E and F: normal boys maturing at early, average, and late tempos (18); groups G and H: GH-treated hypopituitary boys with spontaneous and
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patterns of pubertal growth determined by age at onset
of puberty. These different patterns relate to duration of
pubertal growth which decreases with age at onset of
puberty (Fig. 10). An increased rate of bone maturation
would account for a reduced duration of pubertal growth
and vice versa. In fact, the opposite phenomenon is
observed, a reduced rate of bone maturation being seen
in patients with reduced duration of puberty. This indi-
cates that variations in the rate of bone maturation with
age at onset of puberty do not contribute to the differ-
ences in duration of pubertal growth. Rather, variations
in the rate of bone maturation appear as a compensatory
mechanism which may counteract, to some extent, the
differences in duration of puberty determined by the
timing of its onset.
Effects of age at onset of male puberty on final height. As
shown in Fig. 11, in boys with idiopathic precocious
puberty beginning at a mean age of less than 2.0 yr (n =
5, group B) and 3.9 yr (n = 4, group C), there is a 30.1—
and 20.6-cm reduction of final height (1, 2) when com-
pared to 176.8 cm which is the 50th centile of height for
normal adult males (18). The observations in central
precocious puberty are consistent with the mean adult
height reduction of 23.0 cm seen in nine boys with
untreated congenital adrenal hyperplasia (1, 3, 5,6, group
A). Also, in girls with central precocious puberty, a direct
relationship exists between adult height and age at onset
of puberty (2). In boys with severe sexual precocity, the
reduction in prepubertal height gain, as indicated by
height at onset of puberty (Fig. 11), is much more im-
portant than the increase in pubertal height gain and
accounts for their reduced adult stature (134).
While severe sexual precocity results in impairment of
adult stature (1, 2), similar adult heights are found in
longitudinal studies (18) of normal boys maturing at
early, normal, or late tempos (Fig. 11: groups D, E, and
F). This is in accordance with several reports on normal
adult stature in boys with constitutional delay of puberty,
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FIG. 11. Final height, height at onset of puberty, and total pubertal height gain in relation to age at onset of puberty. Left panels, Individual data
of hypopituitary boys (A, spontaneous puberty, • , testosterone-induced puberty) in relation to bone age [Adapted with permission from J. P.
Bourguignon et al: J Clin Endocrinol Metab 63:376, 1986 (86).] Right panels, Data compiled from the literature and studied in relation to
chronological age; group A: boys with untreated congenital adrenal hyperplasia (1, 3, 5, 6); groups B and C: boys with idiopathic precocious puberty
(1, 2); groups D, E, and F: normal boys maturing at early, average and late tempos (18); groups G and H: GH-treated hypopituitary boys with
spontaneous and testosterone-induced puberty (86); group J: men with hypogonadotrophic hypogonadism (58, 59). [Reproduced with permission
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height reported by some authors (160, 161) may be ex-
plained by differences in parent's height (162, 163).
In GH-deficient patients with idiopathic hypopituitar-
ism, late onset of replacement hGH therapy accounts for
the possible loss of some growth potential as indicated
by short adult stature. However, GH-deficient patients
with spontaneous puberty (Fig. 11: group G) can be
compared with those treated using testosterone (group
H). As shown in Fig. 11, while there is a difference of 3.5
yr of chronological age at onset of puberty between these
two groups of patients, the difference in mean final
height between both groups is only 4.0 cm (86). Analysis
of individual data obtained in hypopituitary boys in
relation to bone age (Fig. 11, left panels) indicates the
existence of opposite variations in prepubertal and pu-
bertal height gains. Since these variations are of similar
importance, they counterbalance one another, resulting
in the absence of obvious differences in final height (86).
Our observations are consistent with those of Burns et
al. (85) and Ranke and Butenandt (87), who found mean
adult height to be, respectively, 2.0 and 2.6 cm greater in
testosterone-treated patients than in those undergoing
spontaneous puberty.
The purest model of severely delayed puberty is pro-
vided by patients with isolated gonadotropin deficiency
not treated before fusion of growth cartilages (group J,
Fig. 11). Recently, Van Dop et al. (59) reported that
height attained by these patients was at, or very close to,
the 50th centile of height for adult males (59). In another
study, mean final height of Kallmann's patients (58), not
treated before age 20, was only 4.2 cm above the 50th
centile.
C. Summary: importance of sex steroid dosage and age at
onset of puberty for subsequent growth and final height
In Table 3 are summarized the observations discussed
in sections IV and V. Sex steroid dosage has some, but
not a major effect, on the immediate growth rate. How-
ever, the dosage affects directly the rate of bone matu-
ration and may, therefore, reduce the total pubertal
height gain. The impact of sex steroid dosage on duration
of puberty and adult stature is unknown.
In both sexes, sexual precocity increases the immediate
growth rate and the total pubertal height gain, as com-
pared to average maturers. There is an increased dura-
tion of puberty which is compensated for by an increased
rate of bone maturation. The increase in total pubertal
height gain is not sufficient to counterbalance the mark-
edly reduced period of prepubertal growth. Thus, final
height is reduced.
In both sexes, delayed puberty reduces the immediate
growth rate and the total pubertal height gain, as com-
pared to average maturers. Also, there is, in boys at least,
a reduced duration of puberty which is compensated for
by a reduced rate of bone maturation. The reduction in
total pubertal height gain counterbalances the increase
in prepubertal height gain. Thus, final height is not
affected.
These conclusions are drawn on the basis of prelimi-
nary observations in pathological conditions and the data
presented warrant further studies. However, some eval-
uation of our therapeutic attitudes can be based on the
data reviewed above.
VI. Therapeutic Implications
In accordance with Prader (164,165), we may conclude
that sex steroids exhibit remarkable interactions with
the dynamics of growth and less striking effects on final
height. This observation has several clinical implications
for the management of patients with short stature and
disorders of puberty.
A. In patients with primary or secondary hypogonad-
ism there is no reason for delaying the onset of sex
steroid therapy or any treatment modality for inducing
sexual maturation. Available information does not indi-
cate significant growth benefit from a late onset of pu-
berty. The psychological correlates of delayed puberty
(166) encourage the practitioner to begin those treat-
ments at an age appropriate for the social or school
context. In panhypopituitary patients, a delayed onset of
























































/edrv/article/9/4/467/2548915 by guest on 10 M
ay 2021
November, 1988 GROWTH IMPACT OF PUBERTY 483
pubertal induction will prolong the total period of GH
therapy without notable differences in final height.
While evidence accumulates against the statural ad-
vantage of a late onset of puberty, some observations
emphasize the need to consider the possible benefits of
a relatively early onset of sex steroid treatment. In pa-
tients with gonadal dysgenesis, the growth response to
sex steroid therapy is greater before 10 yr of bone age; in
hypopituitary girls, estrogen therapy starting at 10-11 yr
of bone age may be required in order to obtain a full
pubertal growth spurt. However, the early induction of
sex steroid therapy warrants further studies, particularly
regarding dosage, before recommendations for such an
approach become acceptable and widespread. Prospec-
tive research protocols employing only minute amounts
of sex steroids might be considered in the first decade of
life.
B. There is a current trend to use lower replacement
doses of sex steroids than in the past to induce optimal
pubertal growth and development. In boys, a monthly
dosage of 25-50 mg testosterone enanthate should be
used for the first year of therapy. In girls, a daily dose of
0.1 Mg/kg ethinyl-esjtradiol or less may be appropriate.
Optimal steroid amounts still need to be determined.
Alternatively, chronic, intermittent administration of
GnRH may induce a physiological increase in endoge-
nous secretion of sex steroids (167). However, such treat-
ment clearly has practical limitations.
C. Since precocious puberty results in reduced adult
stature, it is conceivable that the final growth status of
those patients might be improved by maximally delaying
sexual maturation using superagonists of GnRH (168-
175). However, advancement in bone age results in a
reduction of the pubertal height gain and duration of
GnRH agonist therapy results in a progressive decline of
height velocity below the normal prepubertal limits.
Therefore, in order to maximize residual growth, the
withdrawal of GnRH agonist therapy should not be too
late. The markedly reduced rate of bone maturation seen
at late bone ages may be favorable to final height as long
as a satisfactory linear growth velocity is maintained
during agonist therapy. These various aspects of treat-
ment will not be clarified until adult stature of patients
with precocious puberty can be related to growth param-
eters at the beginning and at the end of treatment.
Although very early onset of puberty reduces adult
stature, very late onset of puberty does not increase adult
height. Therefore, there is no rationale for delaying the
onset of spontaneous puberty beyond the normal bone
ages in patients with very short stature. In very short
pubertal patients with isolated GH deficiency, two pre-
liminary studies (176, 177) indicate some improvement
of predicted adult height with GnRH agonist therapy.
However, long term studies are required before such
treatment on a widespread basis can be considered.
D. Adult stature is less influenced by pubertal growth
than by the height at onset of puberty (92). This finding
indicates that prepubertal growth which is predomi-
nantly controlled by GH, is critical for adult height.
Therefore, early onset of GH therapy and adjustment of
GH dosage to obtain a satisfactory prepubertal height
velocity may be particularly important for adult height.
While interesting data are expected from the widespread
use of biosynthetic GH in short children (110, 178-182),
such intervention warrants further research to determine
the appropriate criteria for treatment and to evaluate
long-term effects.
Finally, the behavioral aspects of growth manipulation
remain uncharted. The premise of "bigger is better,"
requires careful scrutiny. The psychological impact of
improving stature must be balanced against other effects
that therapy and associated laboratory studies may have
on a developing mind. The excitement we bring to our
patients as clinical endocrinologists must be tempered
by the prudence we bring as thoughtful physicians.
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